ACE2 and COVID-19: Deletion of ACE2 in mice translated into early manifestations of muscle weakness with signatures of muscle senescence [111], suggesting that the SARS-CoV-2-dependent downregulation of ACE2 might predispose COVID-19 patients to cachexia.